3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
9
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Gliosarcoma
4
Glioma
4
Glioblastoma
4
Ganglioneuroblastoma
4
Pancreatic Neoplasms
3
Neuroblastoma
3
Vaginal Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Oligodendroglioma
2
Lung Neoplasms
2
Glioma, Subependymal
2
Ependymoma
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma Of Esophagus
2
Wilms Tumor
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Diseases
1
Interventions
pembrolizumab
156
Gemcitabine
139
Capecitabine
121
Paclitaxel
119
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
93
Cisplatin
90
Irinotecan
88
Carboplatin
85
Radiosurgery
83
Cyclophosphamide
71
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
Congresses as Topic
×
Clear all
NCT02387099
2022-02-23
Desiree
GBG Forschungs GmbH
Phase 2
Completed
156 enrolled